Randomized Double-Blind Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
Brief description of study
In this clinical trial, we are testing a drug called glial cell line-derived neurotrophic factor (GDNF) gene transfer to see if it helps people with Multiple System Atrophy (MSA). GDNF gene is delivered to a part of the brain involved in MSA. This study will evaluate the safety of this study drug, and see whether it can improve the course of MSA.
Clinical Study Identifier: s23-01175
ClinicalTrials.gov Identifier: NCT04680065
Principal Investigator:
Patricio Alejandro Millar Vernetti.
Other Investigator:
Maria Alejandra Gonzalez-Duarte Briseno.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.